Literature DB >> 24486210

Subchronic toxicity study of Coptidis rhizoma in rats.

Yong-Hoon Lee1, Duyeol Kim1, Mi Ju Lee1, Myoung Jun Kim1, Ho-Song Jang1, Sun Hee Park1, Jung-Min Lee2, Hye-Yeong Lee1, Beom Seok Han3, Woo-Chan Son4, Ji Hyeon Seok5, Jong Kwon Lee5, Jayoung Jeong5, Jin Seok Kang6, Jong-Koo Kang7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Coptidis Rhizoma (CR) is a medical herb from the family Ranunculacease that has been used to treat gastroenteritis, dysentery, diabetes mellitus, and severe skin diseases. AIM OF THE STUDY: To evaluate the no-observed-adverse-effect level (NOAEL) and the toxicity of CR, following repeat oral administration to rats for 13 weeks.
MATERIALS AND METHODS: CR was administered by oral gavage to groups of rats (n=10/group, each sex) at dose levels of 0 (control), 25, 74, 222, 667 or 2000 mg/kg/day 5 times per week for 13 weeks. Mortality, clinical signs, body weights, food consumption, hematology, serum chemistry, urinalysis, vaginal cytology and sperm morphology, organ weights, gross and histopathological findings were compared between control and CR groups.
RESULTS: Urinalysis showed a significant increase in N-acety1-β-glucosaminidase in males in the 2000 mg/kg/day group (P<0.01). However, no mortality or remarkable clinical signs were observed during this 13-week study. No adverse effects on body weight, food consumption, hematology, serum chemistry, organ weights, gross lesion, histopathology, vaginal cytology, sperm motility, or deformity were observed in the males or female rats treated with CR.
CONCLUSIONS: On the basis of these results, the NOAEL of CR is determined to be 667 mg/kg/day for males and 2000 mg/kg/day for females.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coptidis Rhizoma; Fischer 344 rat; GLP; NOAEL; Subchronic toxicity

Mesh:

Substances:

Year:  2014        PMID: 24486210     DOI: 10.1016/j.jep.2014.01.011

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  7 in total

1.  Preclinical Safety of the Root Extract of Polygala tenuifolia Willdenow in Sprague-Dawley Rats and Beagle Dogs.

Authors:  Ki Young Shin; Beom Young Won; Hyun Jee Ha; Yeo Sang Yun; Hyung Gun Lee
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-05       Impact factor: 2.629

2.  The Rhizome Mixture of Anemarrhena asphodeloides and Coptidis chinensis Ameliorates Acute and Chronic Colitis in Mice by Inhibiting the Binding of Lipopolysaccharide to TLR4 and IRAK1 Phosphorylation.

Authors:  Jin-Ju Jeong; Se-Eun Jang; Supriya R Hyam; Myung Joo Han; Dong-Hyun Kim
Journal:  Evid Based Complement Alternat Med       Date:  2014-09-03       Impact factor: 2.629

Review 3.  From prejudice to evidence: the case of rhizoma coptidis in singapore.

Authors:  Chin Ee Ho; You Li Goh; Chang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-25       Impact factor: 2.629

4.  Subchronic toxicity of herbal compound "Jiedu Huayu" granules in rats.

Authors:  Minggang Wang; Hua Qiu; Rongzhen Zhang; Fuli Long; Dewen Mao
Journal:  BMC Complement Altern Med       Date:  2017-09-06       Impact factor: 3.659

5.  Toxicopathological Evaluation of Hydroethanol Extract of Dianthus basuticus in Wistar Rats.

Authors:  Anofi Omotayo Tom Ashafa; Mutiu Idowu Kazeem
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

Review 6.  Effect of Rhizoma coptidis (Huang Lian) on Treating Diabetes Mellitus.

Authors:  Bing Pang; Xiao-Tong Yu; Qiang Zhou; Tian-Yu Zhao; Han Wang; Cheng-Juan Gu; Xiao-Lin Tong
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-05       Impact factor: 2.629

Review 7.  Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review.

Authors:  Jiasi Wu; Yu Luo; Donghang Deng; Siyu Su; Sheng Li; Li Xiang; Yingfan Hu; Ping Wang; Xianli Meng
Journal:  J Cell Mol Med       Date:  2019-10-17       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.